LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 11 of 535
Next
>>
>
251 to 275 of 13356 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Normalized Growth Rate Inhibition Value
BT-20	Dasatinib	0.12	uM	LJP5	2	D05	72	hr	1097	2080	3877	0.5364	0.4207
BT-20	Dasatinib	0.12	uM	LJP5	3	D05	72	hr	1097	2656	3925	0.6766	0.6172
BT-20	Dasatinib	0.37	uM	LJP6	2	I04	72	hr	1097	1009	3713	0.2717	-0.0466
BT-20	Dasatinib	0.37	uM	LJP6	3	I04	72	hr	1097	1142	3696	0.3090	0.0231
BT-20	Seliciclib	0.04	uM	LJP5	1	J06	72	hr	1097	3907	3735	1.0460	1.0515
BT-20	Seliciclib	0.04	uM	LJP5	2	J06	72	hr	1097	3989	3877	1.0287	1.0313
BT-20	Seliciclib	0.12	uM	LJP5	1	J05	72	hr	1097	3770	3735	1.0093	1.0105
BT-20	Seliciclib	0.12	uM	LJP5	2	J05	72	hr	1097	4166	3877	1.0743	1.0803
BT-20	Seliciclib	0.37	uM	LJP5	2	J04	72	hr	1097	3488	3877	0.8995	0.8870
BT-20	Seliciclib	0.37	uM	LJP5	3	J04	72	hr	1097	3488	3925	0.8886	0.8756
BT-20	Seliciclib	1.11	uM	LJP5	2	J03	72	hr	1097	2937	3877	0.7574	0.7170
BT-20	Seliciclib	1.11	uM	LJP5	3	J03	72	hr	1097	3054	3925	0.7780	0.7448
BT-20	Seliciclib	10	uM	LJP5	1	J01	72	hr	1097	1597	3735	0.4276	0.2366
BT-20	Seliciclib	10	uM	LJP5	2	J01	72	hr	1097	1705	3877	0.4397	0.2738
BT-20	AT-7519	0.04	uM	LJP6	1	K06	72	hr	1097	3009	3610	0.8334	0.7987
BT-20	AT-7519	0.04	uM	LJP6	2	K06	72	hr	1097	3058	3713	0.8234	0.7909
BT-20	AT-7519	0.12	uM	LJP6	2	K05	72	hr	1097	1797	3713	0.4839	0.3237
BT-20	AT-7519	0.12	uM	LJP6	3	K05	72	hr	1097	2069	3696	0.5597	0.4362
BT-20	AT-7519	0.37	uM	LJP6	2	K04	72	hr	1097	916	3713	0.2467	-0.0976
BT-20	AT-7519	0.37	uM	LJP6	3	K04	72	hr	1097	870	3696	0.2354	-0.1241
BT-20	AT-7519	3.33	uM	LJP6	2	K02	72	hr	1097	705	3713	0.1898	-0.2224
BT-20	AT-7519	3.33	uM	LJP6	3	K02	72	hr	1097	470	3696	0.1272	-0.3836
BT-20	AT-7519	10	uM	LJP6	2	K01	72	hr	1097	516	3713	0.1389	-0.3488
BT-20	Dasatinib	1.11	uM	LJP5	2	D03	72	hr	1097	1475	3877	0.3804	0.1764
BT-20	Dasatinib	1.11	uM	LJP5	1	D03	72	hr	1097	1253	3735	0.3355	0.0780

|<
<<
Previous
Page 11 of 535
Next
>>
>
251 to 275 of 13356 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)